Gene · 10892
Papers2,863
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
661 to 680 of 2,863
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Deleterious Genetic Variation Across the NOD Signaling Pathway Is Associated With Reduced NFKB Signaling Transcription and Upregulation of Alternative Inflammatory Transcripts in Pediatric Inflammatory Bowel Disease. | Inflamm Bowel Dis | 2022 | 34978330 | PubTator, text mining | PubMed |
| Loss-of-function SLC30A2 mutants are associated with gut dysbiosis and alterations in intestinal gene expression in preterm infants. | Gut Microbes | 2022 | 34965180 | PubTator, text mining | PubMed |
| Pathogenesis and virulence of Candida albicans. | Virulence | 2022 | 34964702 | PubTator, text mining | PubMed |
| The mechanisms of human lymphoid chromosomal translocations and their medical relevance. | Crit Rev Biochem Mol Biol | 2022 | 34875186 | PubTator, text mining | PubMed |
| Transformed diffuse large B-cell lymphoma from marginal zone lymphoma in the anterior mediastinum: A case report and review of the literature. | J Clin Exp Hematop | 2022 | 34840205 | PubTator, text mining | PubMed |
| Generalized pustular psoriasis (von Zumbusch). | An Bras Dermatol | 2022 | 34838431 | PubTator, text mining | PubMed |
| A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform. | Mod Pathol | 2022 | 34802044 | PubTator, text mining | PubMed |
| Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics. | Mol Ther | 2022 | 34793975 | PubTator, text mining | PubMed |
| CARD9 Expression Pattern, Gene Dosage, and Immunodeficiency Phenotype Revisited. | J Clin Immunol | 2022 | 34791587 | PubTator, text mining | PubMed |
Blood MALT1, Th1, and Th17 cells are dysregulated, inter-correlated, and correlated with disease activity in rheumatoid arthritis patients; meanwhile, MALT1 decline during therapy relates to treatment outcome. | J Clin Lab Anal | 2022 | 34788483 | PubTator, text mining | PubMed |
| Targeting MALT1 for the treatment of diffuse large B-cell lymphoma. | Leuk Lymphoma | 2022 | 34783281 | PubTator, text mining | PubMed |
| An Integrated Taxonomy for Monogenic Inflammatory Bowel Disease. | Gastroenterology | 2022 | 34780721 | PubTator, text mining | PubMed |
| MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer. | Mol Cancer Res | 2022 | 34753803 | PubTator, text mining | PubMed |
| Whole exome sequencing reveals potentially pathogenic variants in a small subset of premenopausal women with idiopathic osteoporosis. | Bone | 2022 | 34743040 | PubTator, text mining | PubMed |
| Discovery and optimization of cyclohexane-1,4-diamines as allosteric MALT1 inhibitors. | Eur J Med Chem | 2022 | 34742013 | PubTator, text mining | PubMed |
| Human immune polymorphisms associated with the risk of cryptococcal disease. | Immunology | 2022 | 34716931 | PubTator, text mining | PubMed |
| MALT1 protease function in regulatory T cells induces MYC activity to promote mitochondrial function and cellular expansion. | Eur J Immunol | 2022 | 34668583 | PubTator, text mining | PubMed |
| The effect of COVID-19 derived cytokine storm on cancer cells progression: double-edged sword. | Mol Biol Rep | 2022 | 34657251 | PubTator, text mining | PubMed |
| Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study | Turk J Haematol | 2022 | 34619856 | PubTator, text mining | PubMed |
| Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. | Br J Haematol | 2022 | 34519021 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10892/papers?page=34